SWOG S1803 (Multiple Myeloma)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Be randomly assigned (like flipping a coin) to 1 of 2 groups
-- One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
-- The other group will take lenalidomide alone


What is the Condition Being Studied?
Multiple myeloma patients who have received a stem cell transplant

Who Can Participate in this Study?

Adults with multiple myeloma who have had a stem cell transplant.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiply myeloma patients live longer.

Study Details

Full Title
SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator

Contacts
Leukemia - Multiple Myeloma DCI Clinical Research Team
Protocol Number
IRB:
PRO00104040

NCT:
NCT04071457
ClinicalTrials.gov
View on ClinicalTrials.gov